Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Links shared publicly online about this topic.

1,107
total visits

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an imp

View full resource at news-medical.net

Tags: Brain, Sleep Disorder, Sleep, Insomnia, Merck & Co.